Analyst Ratings February 9, 2026

Leerink Starts Coverage on Terns Pharmaceuticals, Assigns Outperform and $58 Target

Analyst flags TERN-701 as a potential frontline CML opportunity amid strong liquidity and recent capital raise

By Sofia Navarro TERN
Leerink Starts Coverage on Terns Pharmaceuticals, Assigns Outperform and $58 Target
TERN

Leerink Partners has opened coverage of Terns Pharmaceuticals (TERN) with an Outperform rating and a $58.00 price target, implying roughly 61% upside from the current $37.77 share price. The firm cited early Phase 1 data for TERN-701 and the drug’s potential in the frontline chronic myeloid leukemia market. Terns has also completed a sizeable public offering and amended a regional license agreement for TERN-701.

Key Points

  • Leerink Partners initiated coverage of Terns Pharmaceuticals with an Outperform rating and a $58.00 price target, implying about 61% upside from a $37.77 share price.
  • TERN-701’s early Phase 1 data from the CARDINAL trial suggest higher molecular response rates and a clean safety profile; Leerink sees the frontline CML market as a $4.8 billion opportunity with an additional $1.4 billion in later-line potential.
  • Terns completed a $747.5 million public offering and holds a strong liquidity position with a current ratio of 19.52; the company remains unprofitable over the last twelve months.

Overview

Leerink Partners has initiated coverage of Terns Pharmaceuticals (NASDAQ:TERN) with an Outperform rating and a $58.00 price target. At the time referenced by the research, Terns shares were trading at $37.77, leaving the analyst target representing approximately 61% potential upside from that level. The stock has posted a notable 743% return over the past year, according to InvestingPro data.


Clinical thesis

Leerink highlighted TERN-701, the company’s next-generation allosteric BCR::ABL1 inhibitor in development for chronic myeloid leukemia (CML). The research firm emphasized that the drug builds on the clinical and commercial precedent set by allosteric inhibition in CML, pointing to Novartis’s Scemblix (asciminib) as a relevant comparator. Leerink cited early Phase 1 data from the CARDINAL trial indicating TERN-701 may offer a best-in-class profile, with higher molecular response rates and a clean safety profile that could enable deeper and more durable target suppression.

The analyst view places the greatest value on the frontline CML setting, which Leerink estimates as a $4.8 billion opportunity. The firm also projects an additional $1.4 billion in potential peak revenues from second-line and later uses.


Commercial context and comparators

Leerink noted the commercial success of Scemblix, which InvestingPro data shows was on a $1.6 billion run rate as of the fourth quarter of 2025. The research team used that established adoption of targeted therapy in the CML market as a backdrop for assessing TERN-701’s commercial potential.


Financial position and market metrics

Terns carries a market capitalization of $4.11 billion. The company was not profitable over the last twelve months. InvestingPro data cited by Leerink shows a current ratio of 19.52, indicating liquid assets substantially exceed short-term obligations. The stock’s beta is listed as -0.29, suggesting it has historically exhibited movements that often oppose the broader market direction.


Supporting analyst sentiment and targets

Leerink’s $58 target sits among a range of analyst views. InvestingPro indicates a high analyst target of $70. William Blair has reiterated an Outperform rating, underscoring the clinical activity of TERN-701 in CML. Citizens raised its price target to $57 while maintaining a Market Outperform rating. Jefferies also lifted its target to $70, citing positive Phase 1 data. Leerink’s initiation adds to this cluster of bullish assessments.


Clinical data detail

Phase 1 results cited by multiple analysts show a major molecular response rate of 64% for TERN-701, compared with a 24% rate for Novartis’s Scemblix in similar early-stage results. Those figures were referenced in analyst commentary when assessing the potential clinical differentiation of TERN-701.


Recent corporate actions

Terns recently completed a public offering that raised $747.5 million by selling 18,687,500 shares of common stock at $40.00 per share. The company also amended a license agreement with Hansoh, affecting rights to TERN-701 for oncology indications in territories including mainland China and Taiwan.


Conclusion

Leerink’s initiation underscores Terns’s high-profile position in the CML drug development landscape, driven by the early clinical profile of TERN-701, robust liquidity metrics, and recent capital markets activity. The initiation complements other firms’ bullish assessments while the company remains unprofitable on a trailing-twelve-month basis. The ultimate commercial outcome will depend on continued clinical progress and regulatory and market dynamics.


Risks

  • Clinical risk - The conclusions rely on early Phase 1 data from the CARDINAL trial; subsequent trial results or regulatory review could differ and affect commercial prospects. (Impacts biotech and healthcare sectors)
  • Profitability risk - Terns was not profitable over the past twelve months, which could influence investor sentiment and capital strategy if clinical or commercial timelines shift. (Impacts investor valuations in biotech and capital markets)
  • Market and adoption risk - Competitive dynamics in CML, including established therapies like Scemblix, affect uptake and peak revenue assumptions for TERN-701. (Impacts oncology therapeutics and pharmaceutical commercial forecasts)

More from Analyst Ratings

Stifel Lowers JFrog Target Citing AI-Driven Security Concerns; Maintains Buy Rating Feb 22, 2026 HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026